95 related articles for article (PubMed ID: 19854223)
1. In vitro infectivity assay for prion titration for application to the evaluation of the prion removal capacity of biological products manufacturing processes.
You B; Aubin JT; Le-Hir G; Arzel A; Laude H; Flan B
J Virol Methods; 2010 Mar; 164(1-2):1-6. PubMed ID: 19854223
[TBL] [Abstract][Full Text] [Related]
2. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions.
Klöhn PC; Stoltze L; Flechsig E; Enari M; Weissmann C
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11666-71. PubMed ID: 14504404
[TBL] [Abstract][Full Text] [Related]
3. Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions.
Kitamoto T; Mohri S; Ironside JW; Miyoshi I; Tanaka T; Kitamoto N; Itohara S; Kasai N; Katsuki M; Higuchi J; Muramoto T; Shin RW
Biochem Biophys Res Commun; 2002 Jun; 294(2):280-6. PubMed ID: 12051707
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of removal of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture-based infectivity assay.
Sowemimo-Coker SO; Demczyk CA; Andrade F; Baker CA
Transfusion; 2010 May; 50(5):980-8. PubMed ID: 20003057
[TBL] [Abstract][Full Text] [Related]
5. Extended period of asymptomatic prion disease after low dose inoculation: assessment of detection methods and implications for infection control.
Collins SJ; Lewis V; Brazier MW; Hill AF; Lawson VA; Klug GM; Masters CL
Neurobiol Dis; 2005 Nov; 20(2):336-46. PubMed ID: 16242640
[TBL] [Abstract][Full Text] [Related]
6. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
[TBL] [Abstract][Full Text] [Related]
7. Prion depletion and preservation of biological activity by preparative chaotrope ultracentrifugation.
Seeger H; Julius C; Cozzari C; Calella AM; Dattilo M; Aguzzi A
Biologicals; 2008 Nov; 36(6):403-11. PubMed ID: 18760936
[TBL] [Abstract][Full Text] [Related]
8. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies.
Heger A; Bailey A; Neisser-Svae A; Ertl M; Römisch J; Svae TE
Vox Sang; 2012 May; 102(4):294-301. PubMed ID: 22070802
[TBL] [Abstract][Full Text] [Related]
9. Cell-free formation of misfolded prion protein with authentic prion infectivity.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15818-23. PubMed ID: 17030802
[TBL] [Abstract][Full Text] [Related]
10. Generation of cell lines propagating infectious prions and the isolation and characterization of cell-derived exosomes.
Vella LJ; Hill AF
Methods Mol Biol; 2008; 459():69-82. PubMed ID: 18576148
[TBL] [Abstract][Full Text] [Related]
11. Prion removal by nanofiltration under different experimental conditions.
Yunoki M; Tanaka H; Urayama T; Hattori S; Ohtani M; Ohkubo Y; Kawabata Y; Miyatake Y; Nanjo A; Iwao E; Morita M; Wilson E; MacLean C; Ikuta K
Biologicals; 2008 Jan; 36(1):27-36. PubMed ID: 17890100
[TBL] [Abstract][Full Text] [Related]
12. The in vitro bioassay systems for the amplification and detection of abnormal prion PrP(Sc) in blood and tissues.
Zhang W; Wu J; Li Y; Carke RC; Wong T
Transfus Med Rev; 2008 Jul; 22(3):234-42. PubMed ID: 18572098
[TBL] [Abstract][Full Text] [Related]
13. Protein misfolding cyclic amplification as a rapid test for assessment of prion inactivation.
Murayama Y; Yoshioka M; Horii H; Takata M; Yokoyama T; Sudo T; Sato K; Shinagawa M; Mohri S
Biochem Biophys Res Commun; 2006 Sep; 348(2):758-62. PubMed ID: 16890914
[TBL] [Abstract][Full Text] [Related]
14. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
15. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice.
Safar JG; Scott M; Monaghan J; Deering C; Didorenko S; Vergara J; Ball H; Legname G; Leclerc E; Solforosi L; Serban H; Groth D; Burton DR; Prusiner SB; Williamson RA
Nat Biotechnol; 2002 Nov; 20(11):1147-50. PubMed ID: 12389035
[TBL] [Abstract][Full Text] [Related]
16. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
17. Investigation of prion removal/inactivation from chromatographic gel.
Thyer J; Unal A; Hartel G; Middleton D; Bingham J; Braun M; Uren E; Maher D
Vox Sang; 2006 Nov; 91(4):301-8. PubMed ID: 17105605
[TBL] [Abstract][Full Text] [Related]
18. Immunoaffinity purification and neutralization of scrapie prions.
Gabizon R; McKinley MP; Groth D; Westaway D; DeArmond SJ; Carlson GA; Prusiner SB
Prog Clin Biol Res; 1989; 317():583-600. PubMed ID: 2574871
[TBL] [Abstract][Full Text] [Related]
19. A sensitive and quantitative assay for normal PrP in plasma.
Gregori L; Gray BN; Rose E; Spinner DS; Kascsak RJ; Rohwer RG
J Virol Methods; 2008 May; 149(2):251-9. PubMed ID: 18339433
[TBL] [Abstract][Full Text] [Related]
20. Prion diseases of the central nervous system.
Prusiner SB; DeArmond SJ
Monogr Pathol; 1990; (32):86-122. PubMed ID: 2192281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
